Back to catalogue
№ 277 26 filings · 2021-09-01 → 2026-08-07

OXFORD BIOMEDICA PLC

OXB
Health Care Share price 524p Market cap £634m Overall fit 320 /1000

Weak AI-receiver alignment is the binding constraint — OXB is a cell & gene therapy CDMO, not an AI-adjacent business. High operating leverage and a fair-to-cheap post-derating valuation lift the score, but thin balance sheet and repeated guidance misses cap downside protection.

Fair value range 425p–675p Mid case · £665m
Absolute upside +4.8% vs current market cap
Conviction 3/5 confidence in fair call
Supports the call
  • Multi-year revenue visibility from £193m backlog and £97m contracted orders
  • Fixed-cost base and margin trajectory well disclosed by management
  • Clean balance sheet disclosure post Aug 2025 recapitalisation
Limits the call
  • Aug 2026 guidance cut shows backlog is a weak near-term revenue predictor
  • Fair value highly sensitive to 2027-2030 EBITDA margin assumption (10% vs 30%)
Methodology

EV/EBITDA on 2027-28 exit multiples, cross-checked vs EV/Sales and long-term DCF to 2030 target

In one line · bull case

Post-derating C&GT CDMO with clear fixed-cost operating leverage available at a fair-to-cheap valuation if management can execute on the 25-30% revenue growth guidance and margin ramp toward 20%+ by 2027.

In one line · biggest risk

Further client-ordering slippage or another guidance cut would drain the thin net cash cushion and likely force a dilutive equity raise, given £60m of capex still to spend across 2026-27.

Drivers
AI beneficiary 20 /100
Cell & gene therapy viral vector CDMO with no meaningful AI revenue line; scores low on this dimension.
Operating leverage 78 /100
Fixed manpower and site costs are ~70% of cost base; management guides EBITDA margin from mid-single-digit today to c.30% at scale.
Earnings vs expectations 35 /100
Repeated guidance cuts (Sep 2023, Aug 2026) outweigh the FY25 beat; recent trend is a miss.
Growth momentum 55 /100
Still growing (+30% FY25) but momentum decelerating with Aug 2026 downgrade; medium-term targets intact but pushed out.
Moat 55 /100
30-year viral vector expertise, TetraVecta and inAAVate platforms, and BMS commercial-scale relationship offer some moat but competitive CDMO market.
Earnings quality 55 /100
Non-GAAP Operating EBITDA prominent; some one-offs (Durham gain, restructuring) require adjustment.
Management quality 50 /100
Mathias/Crabtree team has executed the CDMO pivot well but the guidance-cut cadence undermines credibility.
Cyclicality 45 /100
Semi-cyclical exposure to biotech funding environment and client programme timing rather than deeply cyclical.
Leverage 42 /100
Net cash £21m at H1 2026 but drawn $60m of a $125m Oaktree facility with cash covenant; not fortress but not distressed.
Value-trap signals · 4
  • Repeated guidance cuts (Sep 2023, Aug 2026) despite growing backlog
  • Order backlog growing faster than revenue conversion — 'staged ordering' language
  • Share count has grown from ~86m (2021) to 121m (2026) via serial dilution
  • Still loss-making at operating level in H1 2025 despite scale

OXFORD BIOMEDICA PLC (OXB) — Investment Research Note

Executive summary

OXB is a UK-headquartered contract development and manufacturing organisation (CDMO) specialising in viral vectors (lentivirus, AAV, adenovirus) for cell and gene therapy clients, having pivoted to a pure-play CDMO in 2023-24 and expanded via the acquisition of ABL Europe (France, Jan 2024) and a Durham NC facility (Oct 2025). Since the "One OXB" reset, revenues have rebuilt from ~£90m (2023) toward £166-169m (2025) and management expects the business to scale toward c.£500m by 2030 with EBITDA margins approaching 30%, though the recent (Aug 2026) guidance cut has punctured that trajectory in the near term. The single most important valuation issue today is whether the Aug-2026 downgrade (FY26 revenues cut from £220-240m to £180-200m, EBITDA margin cut from >10% to mid-single-digit; FY27 EBITDA margin cut from >20% to at least 10%) marks a temporary client-ordering wobble or a structural deceleration — the stock is down ~47% from January 2026 highs on that fear.

Fair value estimate

  • Fair value range: 425p – 675p per share (implied market cap £515m – £820m)
  • Methodology: EV/EBITDA on 2027-2028 exit multiples, cross-checked with EV/Sales. Key assumptions:
    • FY2027 revenue mid-point £237m (25-30% growth on £185m 2026 mid) 2026-08 trading update
    • FY2027 EBITDA at 10% margin ≈ £24m; FY2028 EBITDA at 15% margin ≈ £42m
    • Applying 12-15x EV/EBITDA (below Lonza/Catalent peer average given execution risk) to FY2028 EBITDA and discounting 2 years at 12% ≈ £405–£515m EV
    • Long-term bull scenario: £500m revenue by 2030 at 25% EBITDA margin = £125m EBITDA; at 10-12x multiple discounted 4 years at 12% ≈ £790-950m EV 2026-08 trading update
    • Net debt: cash £75m less $60m loan drawn ≈ net cash £21m at H1 2026 2026-08 trading update, modest offset
  • Mid-point fair value ≈ 550p / £665m mcap vs current £589.5m at 487p
  • Absolute upside/downside: ~+13% to mid-point (range implies -13% to +39%)

Sector context

  • Sector classification confirmed: Health Care / Health Care Equipment & Services (viral vector CDMO sub-segment) — a picks-and-shovels play on cell & gene therapy pharma pipelines rather than a drug developer.
  • Quality/growth/leverage: growth is above pharma-services average (25%+ guided) but profitability lags — OXB is at the inflection point where scaled peers are already profitable. Balance sheet is weaker than mega-cap peers.
  • Listed peers: Lonza (SIX: LONN, large-cap CDMO, profitable, premium multiple), Catalent (US, now private post-Novo), WuXi Advanced Therapies (part of WuXi AppTec, HK/US). OXB is much smaller and higher-risk than these.

Investment thesis (3 bullets)

  1. Structural growth in cell & gene therapy outsourcing with 2,210 clinical programmes in the pipeline (up from 2,068 in Q2 2024) — OXB now serves 17 new clients signed in H1 2026 alone (>30% above all of 2025) and has a £193m revenue backlog plus £97m in contracted orders, providing multi-year visibility 2026-08 trading update.
  2. Operating leverage on a scaled fixed asset base — with facilities across Oxford, Lyon, Strasbourg, Bedford MA and Durham NC largely built out, management guides to long-term EBITDA margins approaching c.30% as utilisation builds, versus mid-single-digit in FY26. The Bristol Myers Squibb commercial supply agreement for CAR-T lentiviral vectors validates commercial-scale capabilities 2026-08 trading update.
  3. Balance sheet freshly recapitalised for the growth runway — £60m August 2025 placing + $125m Oaktree loan facility (four-year, matures 2029) leaves the company funded to complete the Durham integration and capacity expansions with steady-state capex of £20-25m/yr from 2028 onwards 2025-09 interim results.

Key risks (3 bullets)

  1. Repeated near-term guidance cuts erode credibility — Aug 2026 update cut FY26 revenue by ~15% and FY27 EBITDA margin from >20% to at least 10%, citing client programme deferrals, a big client changing procurement pathway, and a 6-month delay in Durham NC operational readiness. Sep 2023 also brought a significant guidance cut; the pattern signals demand visibility is weaker than the backlog implies 2026-08 trading update; 2023-09 interim results.
  2. Client concentration and biotech funding sensitivity — H1 2025 had just 2 clients >10% of revenue; the going concern narrative repeatedly stress-tests "significant decreases from existing clients". Aug 2026 mentions "a shift in the procurement strategy and change in approval pathway for a larger client" 2025-09 interim results; 2026-08 trading update.
  3. Path-to-profitability funding risk — net cash slipped from £55m (Dec 2025) to £21m (Jun 2026), the Oaktree facility carries covenants (minimum US$20m cash), and further capex of ~£60m across 2026-27 is planned. If EBITDA underperforms the mid-single-digit FY26 target, another equity raise or facility drawdown is plausible 2025-09 interim results.

Operating leverage

Operating leverage is genuinely high and is the central mechanical bull argument. The cost base is dominated by fixed manpower and site costs: H1 2025 manpower was £40.8m and site costs £10.1m against £73.2m revenue — a ~70% fixed-cost mix. Gross margin has moved from 35% (H1 2024) to 43% (H1 2025) on a 44% revenue lift, illustrating incremental drop-through 2025-09 interim results. Management explicitly guides that revenues scaling from ~£185m (2026) to c.£500m (2030) should lift EBITDA margins from mid-single-digit to c.30% — implying incremental revenue conversion to EBITDA of ~35-40%. On a 10-20% upside surprise to 2027 revenue (£24-47m over the mid-case £237m), EBITDA could plausibly rise by £8-19m — a doubling or tripling of forecast EBITDA at the ~£24m base. The inflection points are: (i) filling the Durham NC facility (now Q1 2026 GMP-ready), (ii) UK GMP suite expansion completing H1 2026, (iii) fill-finish capacity coming online. Downside is symmetric: the Aug-2026 EBITDA guide-down from mid-teens to mid-single-digit on a ~10% revenue miss demonstrates negative leverage works too 2026-08 trading update; 2025-09 interim results.

Value-trap signals

  • Repeated guidance cuts (Sep 2023, Aug 2026) — same trading-update pattern of client demand disappointment despite growing "backlog" and "pipeline" figures.
  • Order backlog growth outpacing revenue conversion — contracted orders £97m in H1 2026 but "clients taking a staged approach... taking more time to realise the full value of contracts" is a familiar CDMO warning sign.
  • Equity issuance during the growth ramp — 13.1% dilution in Aug 2025 at £4.31 (vs current 487p) with need for further capex; historical share count has ballooned from ~86m (2021) to 121m today.
  • Loss-making since restructuring — the pure-play pivot required c.£10m one-off restructuring costs (2023) and the business is only now approaching underlying breakeven.
  • Insufficient signals to call it a structural value trap — the underlying market (C&GT) is growing, the client roster is legitimate (BMS, Novartis, plus 44 programmes), and the balance sheet has been reinforced.

Earnings vs expectations

Across the period, OXB has more misses than beats against management's own guidance: (a) FY2023 — guided £126-134m at year start, delivered ~£90m (miss, guidance cut Sep 2023); (b) FY2024 — guided £126-134m, delivered £128.8m (in line); (c) FY2025 — guided £160-170m, delivered £166-169m at upper end (modest beat); (d) H1 2026 — trading update lowered FY26 guidance from £220-240m to £180-200m and cut FY27 EBITDA margin from >20% to at least 10% (material miss). Pattern: management sets aspirational medium-term targets, delivers acceptably in the very short term when contracted, but cuts guidance when late-stage client conversion slips.

Conviction

Conviction: 3 / 5 (moderate).

  • What anchors it: (i) clear multi-year revenue visibility from £193m backlog and £97m contracted orders; (ii) fixed-cost base is well understood and margin trajectory can be modelled from public guidance; (iii) balance sheet is disclosed cleanly with Aug 2025 raise and Oaktree facility terms transparent.
  • What limits it: (i) the Aug 2026 guidance cut shows the "backlog" figure is not a reliable near-term revenue predictor — client ordering cadence is volatile; (ii) fair value swings meaningfully on 2027-2030 margin assumptions (10% vs 20% vs 30% EBITDA margin creates a 3x range on terminal value).

Overall score rationale

OXB is a partial fit for the investor profile. It scores highly on operating leverage (fixed-cost CDMO with margin inflection) and is available at a valuation that no longer prices in the bull case (down 47% from Jan 2026 peak). However, it fails the primary AI-receiver test — this is a biotech-services company, not an AI-adjacent business — and the balance sheet is thin enough that a further guidance miss would likely trigger dilution. The investor's downside-protection preference is only partially satisfied.

Filings consulted · 28

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-08-07Half Year Trading Update And Notice OF Results2026-08-07_9709646_half-year-trading-update-and-notice-of-results.md0.90
  2. 2026-05-07Result OF Agm2026-05-07_9557990_result-of-agm.md0.30
  3. 2026-03-03Capital Markets Day And Investor Conferences2026-03-03_9454741_capital-markets-day-and-investor-conferences.md0.95
  4. 2026-02-24Full Year Trading Update And Notice OF Results2026-02-24_9443607_full-year-trading-update-and-notice-of-results.md0.85
  5. 2025-10-07Acquisition OF US Viral Vector Facility2025-10-07_9154280_acquisition-of-us-viral-vector-facility.md0.64
  6. 2025-09-23Interim Results For 6 Months Ended 30 June 20252025-09-23_9124513_interim-results-for-6-months-ended-30-june-2025.md0.77
  7. 2025-08-15Results OF Placing2025-08-15_9055270_results-of-placing.md0.46
  8. 2025-08-14Proposed Placing OF New Ordinary Shares2025-08-14_9054214_proposed-placing-of-new-ordinary-shares.md0.46
  9. 2025-07-28Half Year Trading Update2025-07-28_9004750_half-year-trading-update.md0.58
  10. 2025-06-23Oxb Completes Acquisition OF US Subsidiary2025-06-23_8941416_oxb-completes-acquisition-of-us-subsidiary.md0.49
  11. 2025-02-17Full Year Trading Update And Notice OF Results2025-02-17_8738509_full-year-trading-update-and-notice-of-results.md0.55
  12. 2024-09-23Interim Results2024-09-23_8431338_interim-results.md0.58
  13. 2024-08-08Half Year Trading Update And Notice OF Results2024-08-08_8355506_half-year-trading-update-and-notice-of-results.md0.41
  14. 2024-04-302023 Annual Report And Accounts2024-04-30_8165580_2023-annual-report-and-accounts.md0.43
  15. 2023-09-20Interim Results2023-09-20_7765954_interim-results.md0.41
  16. 2023-08-14Notice OF Interim Results2023-08-14_7693244_notice-of-interim-results.md0.23
  17. 2023-06-23Result OF Agm2023-06-23_7592265_result-of-agm.md0.07
  18. 2023-04-282022 Annual Report And Accounts2023-04-28_8007_2022-annual-report-and-accounts.md0.24
  19. 2022-09-15Interim Results2022-09-15_7316301_interim-results.md0.23
  20. 2022-08-25Notice OF Interim Results2022-08-25_7047252_notice-of-interim-results.md0.23
  21. 2022-05-27Result OF Agm2022-05-27_7030885_result-of-agm.md0.07
  22. 2022-04-272021 Annual Report And Accounts Amp Agm Notification2022-04-27_7087187_2021-annual-report-and-accounts-amp-agm-notification.md0.24
  23. 2022-03-11Admission OF Conditional Placing Shares2022-03-11_6895693_admission-of-conditional-placing-shares.md0.17
  24. 2022-02-04Admission OF Firm Placing Shares2022-02-04_6746044_admission-of-firm-placing-shares.md0.17
  25. 2022-01-28US Agreement And Proposed Placing OF Shares2022-01-28_6998886_us-agreement-and-proposed-placing-of-shares.md0.17
  26. 2022-01-28Result OF Placing And Primarybid Offer2022-01-28_7000140_result-of-placing-and-primarybid-offer.md0.17
  27. 2021-09-22Interim Results2021-09-22_6514158_interim-results.md0.23
  28. 2021-09-01Notice OF Interim Results2021-09-01_6696593_notice-of-interim-results.md0.23

This research note was authored by a large language model after reading 26 regulatory filings published between 2021-09-01 and 2026-08-07. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.